3-[3-[[2-hydroxy-2-(6-hydroxy-4H-1,4-benzoxazin-8-yl)ethyl]amino]-3-methylbutyl]-6-(trifluoromethyl)-1H-benzimidazol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 3-[3-[[2-hydroxy-2-(6-hydroxy-4H-1,4-benzoxazin-8-yl)ethyl]amino]-3-methylbutyl]-6-(trifluoromethyl)-1H-benzimidazol-2-one
• 化学式: C₂₃H₂₅F₃N₄O₄
• 分子量: 478.5
• InChiKey: LJSPEXIFBFHUIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  106
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• [EN] FUMARIC ACID SALT OF 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY- CHINAZOLIN-6-YLOXY]-1,4-DIAZA-SPIRO[5.5]UNDECAN-5-ONE, ITS USE AS MEDICAMENT AND THE PREPARATION THEREOF<br/>[FR] SEL D'ACIDE FUMARIQUE DE LA 9-[4-(3-CHLORO-2-FLUORO-PHÉNYLAMINO)-7-MÉTHOXY- CHINAZOLIN-6-YLOXY]-1,4-DIAZA-SPIRO[5.5]UNDÉCAN-5-ONE, SON UTILISATION EN TANT QUE MÉDICAMENT ET SA PRÉPARATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014012859A1

  公开（公告）日：2014-01-23

  The present invention relates to a compound of formula (I), which has valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, processes for stereoselectively preparing these compounds, particularly pharmaceutical formulations suitable for inhalation and their use for the treatment of diseases, particularly tumoral diseases, benign prostatic hyperplasia and diseases of the lungs and airways.

  本发明涉及一种具有有价值的药理学特性的化合物(I)，特别是对由酪氨酸激酶介导的信号传导具有抑制作用，以及选择性地制备这些化合物的过程，特别是适用于吸入的制药制剂，以及它们用于治疗疾病，特别是肿瘤性疾病，良性前列腺增生和肺部和气道疾病的用途。
• FUMARIC ACID SALT OF 9-[4-(3-CHLORO-2-FLUORO-PHENYLAMINO)-7-METHOXY- CHINAZOLIN-6-YLOXY]-1,4-DIAZA-SPIRO[5.5]UNDECAN-5-ONE, ITS USE AS MEDICAMENT AND THE PREPARATION THEREOF
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2875020A1

  公开（公告）日：2015-05-27